查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1732847

寡核苷酸合成市場－全球產業規模、佔有率、趨勢、機會和預測（按產品類型、應用、最終用戶、地區和競爭細分，2020-2030 年）

Oligonucleotide Synthesis Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product Type, By Application, By End User, By Region and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 182 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024 年全球寡核苷酸合成市場價值為 42.6 億美元，預計到 2030 年將達到 89.7 億美元，預測期內複合年成長率為 13.21%。該市場在推動生物製藥創新方面發揮著至關重要的作用，是基因編輯、分子診斷和基於 RNA 的治療等應用的基石。該行業的快速擴張與基因組學和個人化醫療領域的突破密切相關，對高保真度、客製化寡核苷酸的需求激增。隨著製藥公司和研究機構越來越關注 RNA 療法和基因標靶治療，對可擴展和精確的寡核苷酸生產的需求不斷增加。臨床試驗（特別是在北美和歐洲）強調了寡核苷酸治療範圍的擴大。透過強勁的投資、不斷成長的生物技術合作以及合成技術的進步，市場已準備好實現持續創新和全球應用。

市場概覽
預測期 2026-2030
2024年市場規模 42.6億美元
2030年市場規模 89.7億美元
2025-2030 年複合年成長率 13.21%
成長最快的領域 療法
最大的市場 北美洲

關鍵市場促進因素

基於RNA的治療

主要市場挑戰

效率和可擴展性

主要市場趨勢

治療進展

目錄

第 1 章：產品概述

第2章：研究方法

第3章：執行摘要

第4章：顧客之聲

第5章：全球寡核苷酸合成市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 依產品類型（合成寡核苷酸產品、試劑、設備和服務）
    • 按應用（研究、治療和診斷）
    • 按最終用戶（學術研究機構、製藥和生物技術公司以及醫院和診斷實驗室）
    • 按地區
    • 按公司分類（2024）
  • 市場地圖

第6章：北美寡核苷酸合成市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 北美：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲寡核苷酸合成市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 歐洲：國家分析
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙

第8章：亞太寡核苷酸合成市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：南美洲寡核苷酸合成市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第10章：中東與非洲寡核苷酸合成市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • MEA：國家分析
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 11 章：市場動態

  • 驅動程式
  • 挑戰

第 12 章：市場趨勢與發展

  • 近期發展
  • 併購

第 13 章：全球寡核苷酸合成市場：SWOT 分析

第 14 章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 顧客的力量
  • 替代治療類型的威脅

第 15 章：競爭格局

  • Thermo Fisher Scientific Inc
  • Agilent Technologies, Inc.
  • Merck KGaA
  • BIO-Synthesis Inc
  • Eurofins Scientific SE
  • Danaher Corporation
  • Ajinomoto Bio-Pharma Services
  • Biogen Inc.
  • Ionis Pharmaceuticals, Inc.
  • Sarepta Therapeutics, Inc.

第 16 章：策略建議

第17章調查會社について,免責事項

簡介目錄
Product Code: 16306

The Global Oligonucleotide Synthesis Market was valued at USD 4.26 billion in 2024 and is projected to reach USD 8.97 billion by 2030, growing at a CAGR of 13.21% during the forecast period. This market plays a vital role in advancing biopharmaceutical innovation, serving as a cornerstone for applications such as gene editing, molecular diagnostics, and RNA-based therapies. The sector's rapid expansion is closely tied to breakthroughs in genomics and personalized medicine, where demand for high-fidelity, tailor-made oligonucleotides has soared. As pharmaceutical companies and research institutions increasingly focus on RNA therapeutics and gene-targeting treatments, the need for scalable and precise oligonucleotide production continues to intensify. Clinical trials-particularly in North America and Europe-underscore the broadening scope of oligonucleotide-based treatments. With robust investments, growing biotech collaborations, and the evolution of synthesis technologies, the market is positioned for sustained innovation and global adoption.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 4.26 Billion
Market Size 2030USD 8.97 Billion
CAGR 2025-203013.21%
Fastest Growing SegmentTherapeutics
Largest MarketNorth America

Key Market Drivers

RNA-Based Therapeutics

RNA-based therapeutics have emerged as a powerful tool for treating a wide range of diseases, propelling the demand for synthetic oligonucleotides. Applications like small interfering RNA (siRNA), antisense oligonucleotides (ASOs), and messenger RNA (mRNA) therapies rely on precise nucleotide synthesis. The global spotlight on mRNA vaccines-particularly those developed for COVID-19-has significantly increased awareness and investment in this segment. Beyond vaccines, RNA-based therapeutics are targeting chronic conditions and rare genetic disorders by altering or silencing specific gene expressions. These therapies require advanced oligonucleotide sequences manufactured with stringent quality and precision standards, highlighting the growing dependence on oligonucleotide synthesis for modern drug development pipelines.

Key Market Challenges

Efficiency and Scalability

Despite strong demand, the industry faces persistent challenges in scaling up oligonucleotide production without compromising quality. High-throughput synthesis processes require consistent optimization to maintain cost-effectiveness, especially as research moves from lab-scale to commercial-scale applications. Additionally, synthesizing complex, longer, or chemically modified oligonucleotides can be resource-intensive, requiring specialized equipment and infrastructure. Compliance with global regulatory standards adds another layer of complexity, necessitating rigorous quality controls. These hurdles can increase production timelines and costs, potentially slowing down commercialization, especially for startups and smaller biopharma companies.

Key Market Trends

Therapeutic Advancements

Therapeutic innovation remains a defining trend in the oligonucleotide synthesis market. The success of mRNA vaccines has validated RNA-based platforms, sparking a surge in R&D investments aimed at tackling conditions like cancer, neurodegenerative diseases, and rare genetic disorders. Oligonucleotides are central to these developments, forming the basis for antisense therapies, RNA interference (RNAi), and gene-editing technologies such as CRISPR. This growing reliance on synthetic nucleic acids has intensified efforts to develop faster, purer, and more cost-efficient synthesis technologies. As pharmaceutical pipelines increasingly include nucleic acid-based drugs, demand for specialized synthesis services and materials is expected to rise significantly, solidifying the sector's strategic importance in modern medicine.

Key Market Players

  • Thermo Fisher Scientific Inc
  • Agilent Technologies, Inc.
  • Merck KGaA
  • BIO-Synthesis Inc
  • Eurofins Scientific SE
  • Danaher Corporation
  • Ajinomoto Bio-Pharma Services
  • Biogen Inc.
  • Ionis Pharmaceuticals, Inc.
  • Sarepta Therapeutics, Inc.

Report Scope

In this report, the Oligonucleotide Synthesis Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Oligonucleotide Synthesis Market, By Product Type:

  • Synthesized Oligonucleotide Products
  • Reagents
  • Equipment
  • Services

Oligonucleotide Synthesis Market, By Application:

  • Research
  • Therapeutics
  • Diagnostics

Oligonucleotide Synthesis Market, By End User:

  • Academic Research Institutes
  • Pharmaceutical & Biotechnology Companies
  • Hospital & Diagnostic Laboratories

Oligonucleotide Synthesis Market, By Region:

  • North America
  • United States
  • Mexico
  • Canada
  • Europe
  • France
  • Germany
  • United Kingdom
  • Italy
  • Spain
  • Asia-Pacific
  • China
  • India
  • South Korea
  • Japan
  • Australia
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Oligonucleotide Synthesis Market.

Available Customizations

Oligonucleotide Synthesis Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validations
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Oligonucleotide Synthesis Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product Type (Synthesized Oligonucleotide Products, Reagents, Equipment, and Services)
    • 5.2.2. By Application (Research, Therapeutics, and Diagnostics)
    • 5.2.3. By End User (Academic Research Institutes, Pharmaceutical and Biotechnology Companies, and Hospital and Diagnostic Laboratories)
    • 5.2.4. By Region
    • 5.2.5. By Company (2024)
  • 5.3. Market Map

6. North America Oligonucleotide Synthesis Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product Type
    • 6.2.2. By Application
    • 6.2.3. By End User
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Oligonucleotide Synthesis Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product Type
        • 6.3.1.2.2. By Application
        • 6.3.1.2.3. By End User
    • 6.3.2. Canada Oligonucleotide Synthesis Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product Type
        • 6.3.2.2.2. By Application
        • 6.3.2.2.3. By End User
    • 6.3.3. Mexico Oligonucleotide Synthesis Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product Type
        • 6.3.3.2.2. By Application
        • 6.3.3.2.3. By End User

7. Europe Oligonucleotide Synthesis Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product Type
    • 7.2.2. By Application
    • 7.2.3. By End User
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Oligonucleotide Synthesis Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product Type
        • 7.3.1.2.2. By Application
        • 7.3.1.2.3. By End User
    • 7.3.2. United Kingdom Oligonucleotide Synthesis Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product Type
        • 7.3.2.2.2. By Application
        • 7.3.2.2.3. By End User
    • 7.3.3. Italy Oligonucleotide Synthesis Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product Type
        • 7.3.3.2.2. By Application
        • 7.3.3.2.3. By End User
    • 7.3.4. France Oligonucleotide Synthesis Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product Type
        • 7.3.4.2.2. By Application
        • 7.3.4.2.3. By End User
    • 7.3.5. Spain Oligonucleotide Synthesis Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product Type
        • 7.3.5.2.2. By Application
        • 7.3.5.2.3. By End User

8. Asia-Pacific Oligonucleotide Synthesis Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product Type
    • 8.2.2. By Application
    • 8.2.3. By End User
    • 8.2.4. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Oligonucleotide Synthesis Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product Type
        • 8.3.1.2.2. By Application
        • 8.3.1.2.3. By End User
    • 8.3.2. India Oligonucleotide Synthesis Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product Type
        • 8.3.2.2.2. By Application
        • 8.3.2.2.3. By End User
    • 8.3.3. Japan Oligonucleotide Synthesis Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product Type
        • 8.3.3.2.2. By Application
        • 8.3.3.2.3. By End User
    • 8.3.4. South Korea Oligonucleotide Synthesis Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product Type
        • 8.3.4.2.2. By Application
        • 8.3.4.2.3. By End User
    • 8.3.5. Australia Oligonucleotide Synthesis Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product Type
        • 8.3.5.2.2. By Application
        • 8.3.5.2.3. By End User

9. South America Oligonucleotide Synthesis Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product Type
    • 9.2.2. By Application
    • 9.2.3. By End User
    • 9.2.4. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Oligonucleotide Synthesis Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product Type
        • 9.3.1.2.2. By Application
        • 9.3.1.2.3. By End User
    • 9.3.2. Argentina Oligonucleotide Synthesis Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product Type
        • 9.3.2.2.2. By Application
        • 9.3.2.2.3. By End User
    • 9.3.3. Colombia Oligonucleotide Synthesis Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product Type
        • 9.3.3.2.2. By Application
        • 9.3.3.2.3. By End User

10. Middle East and Africa Oligonucleotide Synthesis Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product Type
    • 10.2.2. By Application
    • 10.2.3. By End User
    • 10.2.4. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Oligonucleotide Synthesis Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product Type
        • 10.3.1.2.2. By Application
        • 10.3.1.2.3. By End User
    • 10.3.2. Saudi Arabia Oligonucleotide Synthesis Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product Type
        • 10.3.2.2.2. By Application
        • 10.3.2.2.3. By End User
    • 10.3.3. UAE Oligonucleotide Synthesis Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product Type
        • 10.3.3.2.2. By Application
        • 10.3.3.2.3. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Development
  • 12.2. Mergers & Acquisitions

13. Global Oligonucleotide Synthesis Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Treatment Types

15. Competitive Landscape

  • 15.1. Thermo Fisher Scientific Inc
    • 15.1.1. Business Overview
    • 15.1.2. Company Snapshot
    • 15.1.3. Products & Services
    • 15.1.4. Financials (As Reported)
    • 15.1.5. Recent Developments
    • 15.1.6. Key Personnel Details
    • 15.1.7. SWOT Analysis
  • 15.2. Agilent Technologies, Inc.
  • 15.3. Merck KGaA
  • 15.4. BIO-Synthesis Inc
  • 15.5. Eurofins Scientific SE
  • 15.6. Danaher Corporation
  • 15.7. Ajinomoto Bio-Pharma Services
  • 15.8. Biogen Inc.
  • 15.9. Ionis Pharmaceuticals, Inc.
  • 15.10. Sarepta Therapeutics, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer